RxSight previews Q2 revenue of $32 million to $34 million, cuts 2026 sales outlook

The ophthalmic device maker said second-quarter sales were about $27 million and included 24,917 Light Adjustable Lens units, while collaboration revenue from Alcon lifted full-year total revenue guidance.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.